StanleyHHsiaMD

Endocrinology • Los Angeles, CA

Diabetes, Lipid Metabolism

Assistant Professor, Medicine, University of California Los Angeles David Geffen SOM

Join to view full profile

Dr. Hsia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hsia's full profile

Already have an account?

Office
12021 Wilmington Ave
Los Angeles, CA 90059
Phone+1 909-919-9296

Education & Training

University of California (San Diego) Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1996 - 1998
University of Toronto Faculty of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 1996 - 2026
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Fellow (FACE) American Association of Clinical Endocrinology

Clinical Trials

Sitagliptin in Combination With Metformin and Sulfonylurea Start of enrollment: 2008 Jan 01
Completed
Phase 4
Insulin Glargine at Bedtime or in AM Versus NPH Start of enrollment: 2003 Feb 01
Completed
Phase 4
Exercise Dose-Response on Features of the Metabolic Syndrome Start of enrollment: 2004 Oct 01
Completed
Not Applicable
Insulin Glargine Versus Twice-Daily NPH Start of enrollment: 2003 Feb 01
Terminated
Phase 4
Dance Dance Revolution (DDR) in Type 2 Diabetes Start of enrollment: 2009 Feb 01
Completed
Not Applicable
Insulin Resistance in Smokers Undergoing Smoking Cessation Start of enrollment: 2009 Feb 01
Terminated
Not Applicable
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM Start of enrollment: 2015 Sep 01
Completed
Phase 2
Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM Start of enrollment: 2015 Oct 01
Completed
Phase 2
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia Start of enrollment: 2016 Dec 01
Completed
Phase 2
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy Start of enrollment: 2016 Dec 01
Completed
Phase 2
Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus Start of enrollment: 2017 Feb 03
Terminated
Phase 2
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2017 May 24
Completed
Phase 2
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone Start of enrollment: 2019 Jun 03
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

33 citations
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Juan P Frias, Stanley Hsia, Sarah Eyde, Rong Liu, Xiaosu Ma
Lancet. 2023-08-05
76 citations
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.
Arun J Sanyal, Patricia Lopez, Eric J Lawitz, Kathryn J Lucas, Juergen Loeffler
Nature Medicine. 2023-02-01
5 citations
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial.
Juan P. Frias, Enzo Bonora, Luis Nevárez Ruiz, Stanley H. Hsia, Heike Jung
Diabetes, Obesity & Metabolism. 2021-10-01